Authentification abonné
lvrea
Accueil Tous les numéros Volume 27 / Numéro 1 (Janvier 2018) Méd. Intensive Réa., 27 1 (2018) 45-56 Références
Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 27, Numéro 1, Janvier 2018
Respiratoire
Page(s) 45 - 56
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0012
Publié en ligne 16 mars 2018
  • Jolivot PA, Hindlet P, Pichereau C, Fernandez C, Maury E, Guidet B, Hejblum G, (2014) A systematic review of adult admissions to ICUs related to adverse drug events. Crit care 18: 643 [CrossRef] [PubMed] [Google Scholar]
  • Kim S, Oh IJ, Park SY, Song JH, Seon HJ, Kim YH, Yoon SH, Yu JY, Lee BR, Kim KS, Kim YC, (2014) Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis 6: 1209–1217 [PubMed] [Google Scholar]
  • Vahid B, Marik PE, (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133: 528–538 [CrossRef] [PubMed] [Google Scholar]
  • Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, Majeed A, (2010) Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. J R Soc Med 103: 239–250 [CrossRef] [PubMed] [Google Scholar]
  • Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O, (2012) Drug-associated acute lung injury: a population-based cohort study. Chest 142: 845–850 [CrossRef] [PubMed] [Google Scholar]
  • Gibelin A, Parrot A, Maitre B, Brun-Buisson C, Mekontso Dessap A, Fartoukh M, de Prost N, (2016) Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition. Intensive Care Med 42: 164–172 [CrossRef] [PubMed] [Google Scholar]
  • Vial-Dupuy A, Sanchez O, Douvry B, Guetta L, Juvin K, Wermert D, Guérot E, Israël-Biet D, (2013) Outcome of patients with interstitial lung disease admitted to the intensive care unit. Sarcoidosis Vasc Diffuse Lung Dis 30: 134–142 [PubMed] [Google Scholar]
  • Zafrani L, Lemiale V, Lapidus N, Lorillon G, Schlemmer B, Azoulay E, (2014) Acute respiratory failure in critically ill patients with interstitial lung disease. PloS One 9: e104897 [CrossRef] [PubMed] [Google Scholar]
  • Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS, (2017) Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: independent review of four PROFILE trials. Clin Lung Cancer 18:472–9 [CrossRef] [PubMed] [Google Scholar]
  • Barber NA, Ganti AK, (2011) Pulmonary toxicities from targeted therapies: a review. Target Oncol 6: 235–243 [CrossRef] [PubMed] [Google Scholar]
  • Montani D, Seferian A, Savale L, Simonneau G, Humbert M, (2013) Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 22: 244–250 [CrossRef] [PubMed] [Google Scholar]
  • Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS, (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2: 1607–1616 [CrossRef] [PubMed] [Google Scholar]
  • Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, Group BS, (2011) Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 124: 386–394 [CrossRef] [Google Scholar]
  • Teuwen LA, Van den Mooter T, Dirix L, (2015) Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opin Drug Metab Toxicol 11: 1695–1707 [CrossRef] [PubMed] [Google Scholar]
  • White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ, (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182: 396–403 [CrossRef] [PubMed] [Google Scholar]
  • Lioté H, Cadranel J, Lioté F, (2010) Rituximab-induced pneumonitis: steroid therapy or not? Pediatr Pulmonol 45: 412–413 [CrossRef] [PubMed] [Google Scholar]
  • Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G, (2016) Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung cancer 99: 162–165 [CrossRef] [PubMed] [Google Scholar]
  • Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH, (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373: 288–290 [CrossRef] [PubMed] [Google Scholar]
  • Kashiwabara K, Semba H, Fujii S, Tsumura S, (2017) Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer Chemother Pharmacol 79: 705–710 [CrossRef] [PubMed] [Google Scholar]
  • Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P, (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176: 814–818 [CrossRef] [PubMed] [Google Scholar]
  • Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y, (2014) Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry. Jpn J Clin Oncol 44: 1032–1039 [CrossRef] [PubMed] [Google Scholar]
  • Johkoh T, Sakai F, Kusumoto M, Arakawa H, Harada R, Ueda M, Kudoh S, Fukuoka M (2014) Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib-a cohort study. Clin Lung Cancer 15: 448–454 [CrossRef] [PubMed] [Google Scholar]
  • Shah RR, (2016) Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf 39: 1073–1091 [CrossRef] [PubMed] [Google Scholar]
  • Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD, (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 Therapy. J Clin Oncol 35: 709–717 [CrossRef] [PubMed] [Google Scholar]
  • Till BG, Madtes DK, (2012) BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma 53: 1019–1020 [CrossRef] [PubMed] [Google Scholar]
  • Delaunay M, Cadranel J, Lusque A, Meyer N, Gounaut V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J, (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J (in press) [Google Scholar]
  • Matsuno O, (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13: 39 [CrossRef] [PubMed] [Google Scholar]
  • Harada C, Kawaguchi T, Ogata-Suetsugu S, Yamada M, Hamada N, Maeyama T, Souzaki R, Tajiri T, Taguchi T, Kuwano K, Nakanishi Y, (2011) EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med 183: 743–751 [CrossRef] [PubMed] [Google Scholar]
  • Culp JA, Palis RI, Castells MC, Lucas SR, Borish L, (2007) Perioperative anaphylaxis in a 44-year-old man. Allergy Asthma Proc 28: 602–605 [CrossRef] [PubMed] [Google Scholar]
  • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F, (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191 [CrossRef] [PubMed] [Google Scholar]
  • Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M, (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128–2137 [CrossRef] [PubMed] [Google Scholar]
  • Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jaïs X, Sitbon O, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F, (2015) Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 185: 356–371 [CrossRef] [PubMed] [Google Scholar]
  • Turco C, Jary M, Kim S, Moltenis M, Degano B, Manzoni P, Nguyen T, Genet B, Rabier MB, Heyd B, Borg C, (2015) Gemcitabine-induced pulmonary toxicity: a case report of pulmonary veno-occlusive disease. Clin Med Insights Oncol 9: 75–79 [CrossRef] [PubMed] [Google Scholar]
  • Ieki R, Saitoh E, Shibuya M, (2003) Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 22: 179–181 [CrossRef] [PubMed] [Google Scholar]
  • Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T, (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137–139 [CrossRef] [PubMed] [Google Scholar]
  • Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J, (2015) Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol 10: 1148–1155 [CrossRef] [Google Scholar]
  • Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K, (2013) Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol 31: e15–e17 [CrossRef] [PubMed] [Google Scholar]
  • Otoshi T, Kataoka Y, Nakagawa A, Otsuka K, Tomii K, (2016) Clinical features and outcomes of diffuse alveolar hemorrhage during antithrombotic therapy: a retrospective cohort study. Lung 194: 475–481 [CrossRef] [PubMed] [Google Scholar]
  • Kurimoto R, Sekine I, Iwasawa S, Sakaida E, Tada Y, Tatsumi K, Takahashi Y, Nakatani Y, Imai C, Takiguchi Y, (2015) Alveolar hemorrhage associated with pemetrexed administration. Intern Med 54: 833–836 [CrossRef] [PubMed] [Google Scholar]
  • Ono A, Takahashi T, Oishi T, Sugino T, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Nakajima T, Endo M, Yamamoto N, (2013) Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol 31: e417–e419 [CrossRef] [PubMed] [Google Scholar]
  • Lioté H, Lioté F, Seroussi B, Mayaud C, Cadranel J, (2010) Rituximab-induced lung disease: A systematic literature review. Eur Respir J 35: 681–687 [CrossRef] [PubMed] [Google Scholar]
  • Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D, (2013) Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143: 858–861 [CrossRef] [PubMed] [Google Scholar]
  • Mankikian J, Lioger B, Diot E, D’Halluin P, Lissandre S, Marchand Adam S, Mercier E, Beau Salinas F, (2014) Pulmonary toxicity associated with the use of lenalidomide: case report of late-onset acute respiratory distress syndrome and literature review. Heart Lung 43: 120–123 [CrossRef] [PubMed] [Google Scholar]
  • Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin JF, Mayaud C, Cadranel J, (2001) Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 164: 1186–1191 [CrossRef] [PubMed] [Google Scholar]
  • Souza CA, Muller NL, Johkoh T, Akira M, (2006) Drug-induced eosinophilic pneumonia: high-resolution CT findings in 14 patients. AJR Am J Roentgenol 186: 368–373 [CrossRef] [PubMed] [Google Scholar]
  • John RC St, Allen JN, Pacht ER, (1990) Postoperative respiratory failure due to acute eosinophilic pneumonia. Intensive Care Med 16: 408–410 [CrossRef] [PubMed] [Google Scholar]
  • Griffiths CL, Gutierrez KC, Pitt RD, Lovell RD, (2014) Eosinophilic pneumonia induced by ceftaroline. Am J Health Syst Pharm 71: 403–406 [CrossRef] [PubMed] [Google Scholar]
  • Salmeron S, Brochard L, Rain B, Herve P, Brenot F, Simonneau G, Duroux P, (1988) Early neutrophil alveolitis after rechallenge in drug induced alveolitis. Thorax 43: 647–648 [CrossRef] [PubMed] [Google Scholar]
  • Khalil H, Molinary E, Stoller JK, (1993) Diclofenac (Voltaren)-induced eosinophilic pneumonitis. Case report and review of the literature. Arch Intern Med 153: 1649–1652 [CrossRef] [PubMed] [Google Scholar]
  • Gruson D, Hilbert G, Valentino R, Vargas F, Chene G, Bebear C, Allery A, Pigneux A, Gbikpi-Benissan G, Cardinaud JP, (2000) Utility of fiberoptic bronchoscopy in neutropenic patients admitted to the intensive care unit with pulmonary infiltrates. Crit Care Med 28: 2224–2230 [CrossRef] [PubMed] [Google Scholar]
  • Cordonnier C, Escudier E, Verra F, Brochard L, Bernaudin JF, Fleury-Feith J, (1994) Bronchoalveolar lavage during neutropenic episodes: diagnostic yield and cellular pattern. Eur Respir J 7: 114–120 [CrossRef] [PubMed] [Google Scholar]
  • Endo M, Johkoh T, Kimura K, Yamamoto N, (2006) Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung cancer 52: 135–140 [CrossRef] [PubMed] [Google Scholar]
  • Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H, (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258: 41–56 [CrossRef] [PubMed] [Google Scholar]
  • Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC, (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20: 1245–1259 [CrossRef] [PubMed] [Google Scholar]
  • Larsen BT, Vaszar LT, Colby TV, Tazelaar HD, (2012) Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathology 36: 509–516 [CrossRef] [Google Scholar]
  • Feenstra JF, Hickey BP, Blackwell EA, (2004) Acute respiratory failure associated with cladribine pneumonitis. Intern Med J 34: 583–584 [CrossRef] [PubMed] [Google Scholar]
  • Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD, (2002) Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 126: 1064–1070 [PubMed] [Google Scholar]
  • Piciucchi S, Dubini A, Tomassetti S, Casoni G, Ravaglia C, Poletti V, (2015) A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. Am J Respir Crit Care Med 191: 104–106 [CrossRef] [PubMed] [Google Scholar]
  • Helman DL Jr., Byrd JC, Ales NC, Shorr AF, (2002) Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 122: 785–790 [CrossRef] [PubMed] [Google Scholar]
  • Schwarz MI, Albert RK, (2004) “Imitators” of the ARDS: implications for diagnosis and treatment. Chest 125: 1530–1535 [CrossRef] [PubMed] [Google Scholar]
  • Lioté H, Seroussi B, Bouaud J, Voiriot G, Mayaud C, (2007) PneumoDoc: a computer-based decision-making system for drug-related pulmonary disease. Rev Pneumol Clin 63: 193–201 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.